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Abstract Consistent and robust manufacturing is essential
for the translation of cell therapies, and the utilisation
automation throughout the manufacturing process may
allow for improvements in quality control, scalability,
reproducibility and economics of the process. The aim of
this study was to measure and establish the comparability
between alternative process steps for the culture of hiPSCs.
Consequently, the effects of manual centrifugation and
automated non-centrifugation process steps, performed
using TAP Biosystems’ CompacT SelecT automated cell
culture platform, upon the culture of a human induced
pluripotent stem cell (hiPSC) line (VAX001024c07) were
compared. This study, has demonstrated that comparable
morphologies and cell diameters were observed in hiPSCs
cultured using either manual or automated process steps.
However, non-centrifugation hiPSC populations exhibited
greater cell yields, greater aggregate rates, increased
pluripotency marker expression, and decreased differenti-
ation marker expression compared to centrifugation
hiPSCs. A trend for decreased variability in cell yield was
also observed after the utilisation of the automated process
step. This study also highlights the detrimental effect of the
cryopreservation and thawing processes upon the growth
and characteristics of hiPSC cultures, and demonstrates
that automated hiPSC manufacturing protocols can be
successfully transferred between independent laboratories.
Keywords Automation  Centrifugation  Pluripotent stem
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Introduction
The reprogramming of adult somatic cells into pluripotent
stem cells, known as induced pluripotent stem cells
(iPSCs), was first achieved by Takahashi and Yamanaka
[1] through the overexpression of Oct3/4, Sox2, Klf4, and
c-Myc transcription factors. If cell therapies derived from
Human iPSCs (hiPSCs) are to gain adoption in healthcare,
consistent and scalable manufacturing processes will be
essential. The automation of cell culture holds significant
promise for the improvement of quality control, scalability,
reproducibility and economics of the process [2, 3].
In this study, an automated culture process with an
incorporated manual centrifugation process step, hence
known as the ‘centrifugation’ process, was compared to a
validated and fully automated culture process, which
included an alternative ‘non-centrifugation’ process step
resulting in residual dissociation agent remaining within
the culture, hence known as the ‘non-centrifugation’ pro-
cess. This allowed for the direct comparison of the effect of
a manual centrifugation and an automated non-centrifu-
gation process step upon hiPSC growth and characteristics
by minimising the variability associated with fully manual
culture processes. The differences in process steps between
these processes are illustrated in Fig. 1.
The CompacT SelecT automated cell culture platform
(TAP Biosystems, Royston, UK) (Fig. 2); which utilises an
incubator carousel to store cell culture flasks, multiple
peristaltic pumps to dispense cell culture reagents, and a
robotic arm to replicate many of the process steps involved
in manual cell culture; was utilised in this study. This
platform also has an automated cell counter incorporated;
which utilises Trypan blue exclusion and automated
imaging software to determine viable cell density, viability,
and aggregate rate. The CompacT SelecT has previously
been validated for the culture of hMSCs, hESCs and
hiPSCs as aggregates [4–6]. Automated hiPSC culture
protocols were transferred from I-Stem (E´vry, France) to
the Centre for Biological Engineering (Loughborough
University, UK). However, these protocols required adap-
tation due to differences in the capabilities of the auto-
mated platforms located at each site. New protocols were
generated to allow for the seeding and passage of a single
T175 flask, and daily microscopy was utilised to determine
culture confluency. The fully automated, non-centrifuga-
tion hiPSC culture protocol was also adapted to incorporate
a centrifugation process step. This adapted protocol was
utilised in the manual, centrifugation process arm of the
experiment. By undertaking a process transfer between
Fig. 1 Process diagram illustrating the differences between the CompacT SelecT manual (centrifugation) and automated (non-centrifugation)
hiPSC culture process steps
Fig. 2 TAP Biosystems’ CompacT SelecT automated cell culture
platform (TAP Biosystems, Part of the Sartorius Stedim Biotech
Group, Royston, UK)
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laboratories, product and process comparability between
sites can be demonstrated, which can be crucial to
achieving regulatory approval for biological products [7].
The recommended passage procedure for the
VAX001024c07 hiPSC line involves the dissociation of the
cells into a single cell suspension and their re-seeding onto
Matrigel-coated tissue culture plastic. It has been identified
that the dissociation of pluripotent stem cells into a single
cell suspension can lead to apoptosis [8, 9]. However, the
maintenance of pluripotent stem cell morphology over ten
passages despite dissociation into single cells has been
demonstrated [10]. Rho-associated protein kinase (ROCK)
inhibitor has been shown to allow for the survival and
maintenance of pluripotency of pluripotent stem cells after
dissociation [11], as well as improved viable hiPSC
recovery after cryopreservation [12, 13]. In this study,
ROCK inhibitor was added to the culture during the initial
seeding, passage and cryopreservation processes, as well as
on Day 1 after initial seeding or passage.
Therefore, the aim of this study was to measure and
establish the comparability between alternative process
steps for the culture of the hiPSCs. This investigation
examined the effects of manual and automated process
steps upon the morphology, cell diameter, viable cell yield,
viability, aggregate rate and pluripotency marker expres-
sion of the VAX001024c07 hiPSC line.
Materials and methods
hiPSC culture
Creation of a hiPSC working bank
The VAX001024c07 hiPSC line was generated at I-Stem
by transducing human myoblasts with the four Yamanaka
factors (OSKM) using amphotropic retroviruses and
adapting the resulting hiPSCs to single cell culture, as
described by Massouride`s et al. [14]. Before transfer to
Loughborough University, these cells had previously
undergone 22 passages in the presence of feeder cells, and
9 passages in feeder-free conditions. These cells were then
manually expanded, following the process steps and
parameters of the automated ‘non-centrifugation’ culture
process as closely as possible, to generate a working cell
bank (‘Baseline hiPSCs’).
hiPSC centrifugation culture method
Before any automated protocol was initiated on the Com-
pacT SelecT platform (TAP Biosystems), the machine was
prepared for use by loading sufficient consumables and
reagents, and by performing calibrating and priming steps to
ensure that the required volumes of each reagent is dis-
pensed. As a result of test experimental runs performed
during the process transfer between sites, it was determined
that an additional passage prior to the experimental pas-
sages, or ‘pre-experimental’ passage, and an increased initial
seeding density were required to mitigate the detrimental
effects of cryopreservation upon hiPSC recovery. Therefore,
these steps were incorporated into both the centrifugation
and non-centrifugation experimental arms. An overview of
the experimental workflow is illustrated in Fig. 3.
For each of the four centrifugation experimental runs,
Baseline hiPSCs were thawed, suspended in pre-warmed
mTeSR1 medium (StemCell Technologies, Vancouver,
Canada), centrifuged at 276 RCF for 5 min, the supernatant
aspirated, the cell pellet resuspended in mTeSR1 medium
with ROCK inhibitor (10 lM) (Y-27632, StemCell Tech-
nologies), and the suspension transferred into a 50 ml
centrifuge tube which was then placed in the static holder
of the CompacT SelecT before an automated seeding
Fig. 3 Process diagram describing the pre-experimental and experimental centrifugation and non-centrifugation passages. WCB working cell
bank
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protocol was performed. During this protocol, the cells
were mixed, a cell count was performed, the cells were
diluted, and 4.75 9 106 cells (2.7143 9 104 cells/cm2)
were transferred into a new Matrigel-coated barcoded T175
flask (P22 ? 12). MatrigelTM (BD Biosciences, San Jose,
USA) was diluted with KnockoutTM DMEM (322.5 lg/ml)
(Life Technologies, Thermo Fisher Scientific, Waltham,
USA). A medium exchange with mTESR1 10 lM ROCK
inhibitor solution was performed 4 h after seeding, once
the viable cells had adhered to the flask, to remove dead or
non-adherent cells; as well as 24 h after initial seeding.
Subsequently, every 24 h, confluency was examined using
microscopy and a medium exchange with mTeSR1 was
performed.
To passage these cells, after approximately 7 days and
once 80 % confluent, the cells were pre-treated with 10 lM
ROCK inhibitor solution for 1 h and an automated pre-
centrifugation passage protocol was performed to dissoci-
ate the cells with AccutaseTM (StemCell Technologies);
agitate any non-dissociated cells; quench with mTeSR1;
and obtain cell count, viability, aggregation and cell
diameter data. The mother flask containing the dissociated
cells was then ‘‘outfeeded’’, which refers to the temporary
ejection of a flask from the platform and allows the flask to
be re-imported and recognised by the CompacT SelecT
software. The cell suspension was then centrifuged, the
cells were resuspended in fresh mTeSR1, thoroughly
mixed, and reintroduced into the mother T175 flask which
was imported back into the CompacT SelecT. Next, an
automated post-centrifugation protocol was utilised to
perform a cell count, add 3 ml of 10 lM ROCK inhibitor
solution, isolate 8 9 106 cells, dilute the isolated cells,
seed the appropriate number of Matrigel-coated daughter
flasks with 3.5 9 106 cells, and add additional mTeSR1
and ROCK inhibitor solution to each daughter flask. Daily
medium exchanges were performed after each passage,
with ROCK inhibitor added on Day 1. The following for-
mula was utilised to determine the cumulative population
doublings (CPDs) for each hiPSC experimental run:
CPDs ¼ ½Time of Final Cell Count ðDaysÞ
 Time of Seeding ðDaysÞ=Population Doubling Time ðDaysÞ
For each passage, identical protocols were utilised.
However, during the pre-experimental passage, each T175
flask was passaged into a single T175 daughter flask,
whereas in later passages two daughter flasks were seeded
from each mother flask. This low flask expansion rate was
utilised, in accordance with the I-Stem manufacturing
protocols, to allow for a sufficient number of passages to
facilitate hiPSC recovery post-thaw, and to allow for
multiple batches to be performed without exceeding the
capacity of the CompacT SelecT incubator. It must be
noted that centrifugation cell count data could not be col-
lected during the 2nd passage of the fourth batch due to a
malfunction of the Cedex Automated Cell Counter, which
is integrated in the CompacT SelecT platform. After three
passages, and once 80 % confluent, the four T175 flasks
generated per batch were pre-treated with 10 lM ROCK
inhibitor solution, harvested, the cells pooled, counted,
resuspended in Cryostor CS-10 freezing medium, and
cryopreserved.
hiPSC non-centrifugation culture method
For each of the four non-centrifugation experimental runs,
similar cell revival and resuspension processes to those
described in the hiPSC centrifugation culture method were
utilised during seeding of the mother flask, as well as the
inclusion of a ‘pre-experimental’ passage and an increased
initial seeding density. Furthermore, an identical automated
seeding protocol and medium exchange frequency was
utilised.
Once 80 % confluent, the cells were pre-treated with
10 lM ROCK inhibitor solution for 1 h and an automated
non-centrifugation protocol was performed, in which
residual dissociation agent was not removed and was
carried over throughout culture. During this protocol, the
cells were washed with Accutase, incubated with Accu-
tase for 10 min at 37 C, agitated to dissociate any
adherent cells, and quenched with mTeSR1 medium with
10 lM ROCK inhibitor solution. A cell count was also
performed, 8 9 106 cells were isolated, isolated cells
were diluted, and the appropriate number of new bar-
coded Matrigel-coated daughter flask were seeded with
3.5 9 106 cells.
For each passage, identical pre-treatment, and non-
centrifugation protocols were utilised. Similarly to the
centrifugation arm, after the pre-experimental passage, the
number of daughter flasks seeded from each mother flask
increased to two. Due to a malfunction of the Cedex
Automated Cell Counter, non-centrifugation granddaughter
flask cell count data could not be collected for the fourth
batch. After three passages, identical harvesting and
downstream processing steps to those described for the
centrifugation arm were utilised.
Pluripotency marker expression
Baseline (P22 ? 11), centrifugation (P22 ? 15) and non-
centrifugation (P22 ? 15) hiPSCs were prepared for mul-
ticolour flow cytometry following the manufacturer’s
instructions (BD Stemflow, BD Biosciences) after a cell
count was performed. To determine the immunophenotype
of each hiPSC population, multicolour flow cytometry was
performed using antibodies for two markers which are
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commonly used to identify undifferentiated pluripotent
stem cells, specifically Stage-Specific Embryonic Antigen-
3 (SSEA-3) and Tumour-Related Antigen-1-81 (TRA-1-
81), and for one marker which has been identified as a
negative marker of pluripotent cells, specifically SSEA-1
[15, 16].
Briefly, after fixation, the cells were added to flow
cytometry tubes (BD Biosciences) containing either; one of
the FITC SSEA-1, PE SSEA-3 and Alexa Fluor 647 TRA-
1-81 antibodies, or one of the FITC, PE and Alexa Fluor
647 isotype controls. Replicates of each of the specific
stain and isotype control tubes were generated, and all
tubes incubated in the dark on ice for 30 min and washed
with stain buffer. Control beads were also prepared with
the appropriate antibodies. Prior to analysing hiPSC sam-
ples on the BD FACSCanto II (BD Biosciences) using the
FACSDiva software version 6.1.3, unstained negative
beads were analysed. A gate was then set around the singlet
bead population on the FSC vs SSC plot; and the FITC, PE,
and Alexa Fluor 647 stained control beads were analysed to
ensure that the positive populations fitted on the FSC and
SSC scales, and to calculate compensation. Unstained cells
were then analysed, and a gate was set around the main cell
population on the FSC vs SSC plot. Next, the isotype
controls were analysed, followed by the hiPSC samples.
For analysis, the flow cytometry data was exported in FCS
3 format and analysed using FlowJo software v10. Scatter
plots for the isotype controls are presented in Fig. 13a–c in
Appendix.
Statistical analyses
Viable cell density, viable cell yield, population doubling
time, viability, cell diameter, and aggregate rate data for
pre-centrifugation, post-centrifugation and non-centrifuga-
tion hiPSCs across all passages was analysed using two-
way analysis of variance (ANOVA) multiparameter anal-
yses, through the IBM SPSS statistical software, to deter-
mine significant differences. Furthermore, one-way
ANOVAs were utilised to assess the significance of dif-
ferences in viable cell density, viable cell yield, and via-
bility of pre-centrifugation, post-centrifugation and non-
centrifugation of hiPSCs within the 2nd passage. One-way
ANOVAs were also used to assess the significance of
differences between the standard deviations (SD) of the
viable cell densities, viable cell yields, and viabilities of
pre-centrifugation, post-centrifugation, and non-centrifu-
gation of hiPSCs, in each of the four batches, from the
second passage. The cut-off value for statistical signifi-
cance (p) was set at 0.05.
Results
Morphology
After visual examination, it was determined that single
cells with multiple long, thin lamellipodia were generated
early in culture (Days 0–1) (Fig. 4a, b), and that, after 48 h
of culture, hiPSCs began to form small colonies with a
rounded morphology, often with few spontaneously dif-
ferentiated cells at their periphery (Fig. 5a, b). Exemplar
images of small hiPSC colonies, cultured using the cen-
trifugation and non-centrifugation protocols, visualised
under a higher magnification are presented in Fig. 14 in
Appendix. Cell populations cultured using centrifugation
and non-centrifugation process steps observed similar
morphologies both early (Days 0–1) and later (CDay 2) in
culture. However, it appeared that hiPSCs cultured using
the non-centrifugation process step formed small colonies
more rapidly than those cultured using the centrifugation
process step, despite the addition of ROCK inhibitor early
in culture (Days 0–1).
Cell diameter
After comparing the cell diameter of hiPSC populations
across all passages, it was determined that cells from the
pre-experimental passage (P22 ? 12/P34), cultured after
cryopreservation, were significantly larger than cells from
the 1st (P22 ? 13/P35) and 2nd (P22 ? 14/P36) passages
regardless of the process step utilised (p\ 0.001) (Fig. 6).
No significant difference in cell diameter was observed
between Pre-, post- and non-centrifugation hiPSCs popu-
lations across all passages, demonstrating that neither the
automated nor the manual process steps significantly
influenced cell size.
Pluripotency marker expression
Human iPSCs have been previously demonstrated to
express the pluripotency markers TRA-1-81 and SSEA-3,
and to lack the expression of the SSEA-1 differentiation
marker [17]. In this study, single cell analysis of the
immunophenotype of baseline (P22 ? 11), centrifugation
(P22 ? 15) and non-centrifugation (P22 ? 15) of hiPSCs
revealed that the majority of cells in each population co-
expressed SSEA-3 and TRA-1-81 (50.3–70.8 %) (Figs. 7,
8, 9), and that the expression of SSEA-1 was low in all
hiPSC populations (\20 %). These findings indicate that
each of the baseline, centrifugation and non-centrifugation
hiPSC populations contained predominantly pluripotent
cells.
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However, after comparing the immunophenotype of
hiPSC populations from each condition, it was observed
that centrifugation of hiPSC populations exhibited a
reduced pluripotency marker expression, and an
increased differentiation marker expression, compared to
both baseline and non-centrifugation of hiPSC
populations.
Viable cell yield
As illustrated in Fig. 10, the viable cell yields of hiPSC
populations in the 1st (P35/P22 ? 13) (p = 0.003) and 2nd
(P36/P22 ? 14) (p\ 0.001) passages were significantly
greater than those in the pre-experimental (P34/P22 ? 12)
passage regardless of the process step utilised. It was also
Fig. 4 hiPSC batch 3 post-
centrifugation (Ce) (a) and non-
centrifugation (NC) (b) Day 1
Morphology
Fig. 5 hiPSC batch 3 post-
centrifugation (Ce) (a) and non-
centrifugation (NC) (b) Day 4
Morphology
Fig. 6 The average cell diameter of pre-centrifugation, post-cen-
trifugation and non-centrifugation hiPSCs from all four batches and
over the pre-experimental [replicates (n) = 4], 1st [replicates
(n) = 4], and 2nd passages [replicates (n) = 6]. Standard deviations
are plotted as error bars. Asterisk (*) denotes significance over 1st
and 2nd passages (p = 0.05)
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observed that pre-centrifugation hiPSC populations
demonstrated significantly greater viable cell yields com-
pared to post-centrifugation hiPSC populations over all
passages (p = 0.007). Furthermore, non-centrifugation
hiPSC populations exhibited significantly greater viable
cell yields compared to post-centrifugation hiPSC popula-
tions over all passages (p = 0.028). Although no signifi-
cant difference in viable cell yield between pre-
centrifugation and non-centrifugation hiPSC populations
was observed, given the reduction in viable cell yield after
the centrifugation process, it is apparent that a greater
viable cell yield is achievable when the non-centrifugation
process step is utilised. Mean cumulative population dou-
blings (CPDs) of 17.61 and 17.72 were achieved after
culture over three passages utilising the centrifugation and
non-centrifugation process steps, respectively.
By comparing the standard deviations of viable cell
yields for pre-, post- and non-centrifugation hiPSC popu-
lations, it was determined that no significant difference in
the variability in viable cell yield was observed between
process steps in the 2nd passage. However, a non-signifi-
cant trend for a lower variability in viable cell yield in non-
centrifugation samples compared to post-centrifugation
samples, may exist.
Viability
No significant difference in hiPSC viability was observed
between the pre-experimental (P34/P22 ? 12), 1st (P35/
P22 ? 13) or 2nd (P36/P22 ? 14) passages (Fig. 11). It
was also demonstrated that the viability of non-centrifu-
gation hiPSC samples was significantly lower than that of
post-centrifugation samples across all passages
(p\ 0.001), and was significantly lower than that of pre-
centrifugation samples in the 2nd passage (p = 0.005).
Furthermore, significantly greater hiPSC viability was
observed in post-centrifugation samples compared to pre-
centrifugation samples in the 2nd passage (p = 0.045).
Fig. 7 Scatter plots demonstrating multicolour flow cytometric analysis of pluripotency and differentiation marker co-expression of baseline
hiPSCs from the working cell bank (P22 ? 11)
Fig. 8 Scatter plots demonstrating multicolour flow cytometric analysis of pluripotency and differentiation marker co-expression of
centrifugation hiPSCs (P22 ? 15)
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Finally, when the standard deviations of hiPSC viabilities
were compared, no significant difference in the variability
in hiPSC viability between process steps was observed,
although non-significant trends for greater variability in
non-centrifugation hiPSC samples, as well as those from
the pre-experimental passage.
Average aggregate rate
By comparing the average aggregate rate of hiPSC popu-
lations from all four batches, over three passages, it was
determined that the aggregate rate of populations in the pre-
experimental passage (P34/P22 ? 12) were significantly
higher than those from the 1st (P35/P22 ? 13) (p = 0.001)
and 2nd passages (P36/P22 ? 14) (p = 0.017), regardless
of the process step utilised (Fig. 12). It was also determined
that significantly greater aggregation was observed in pre-
centrifugation hiPSC samples compared to post-centrifuga-
tion samples over all passages (p = 0.001). Furthermore, it
was determined that aggregate rate was significantly higher
in non-centrifugation hiPSC samples compared to post-
centrifugation samples, across all passages (p\ 0.001).
Fig. 9 Scatter plots demonstrating multicolour flow cytometric analysis of pluripotency and differentiation marker co-expression of non-
centrifugation hiPSCs (P22 ? 15)
Fig. 10 The average pre-centrifugation, post-centrifugation and non-
centrifugation viable hiPSC yield per flask over the pre-experimental
(P34/P22 ? 12) [replicates (n) = 4], 1st (P35/P22 ? 13) [replicates
(n) = 4], and 2nd (P36/P22 ? 14) [replicates (n) = 6] passages, and
across four batches. Standard deviations are plotted as error bars.
Asterisk (*) denotes significance over pre-experimental passage
(p = 0.05). Number sign (#) denotes significance of pre-centrifuga-
tion hiPSCs over post-centrifugation hiPSCs over all passages
(p = 0.05). Dagger symbol () denotes significance of non-centrifu-
gation hiPSCs over post-centrifugation hiPSCs over all passages
(p = 0.05)
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Discussion and conclusions
The VAX001024c07 hiPSC line utilised in this study was
selected as it has previously been adapted to single cell,
monolayer culture and has been demonstrated by I-Stem
to be amenable to culture using the CompacT SelecT
automated platform. This study has demonstrated that
comparability in cell morphology and diameter was
observed between hiPSCs cultured using manual and
automated process steps. Furthermore, no significant dif-
ference in cell diameter was observed between process
steps. However, non-centrifugation hiPSC populations
exhibited greater cell yields, greater aggregate rates, and
lower cell viabilities compared to centrifugation hiPSCs.
The decrease in viable cell yield after the manual, cen-
trifugation process step may indicate that further optimi-
sation of this step is required for the culture of hiPSCs. In
particular, optimisation of the RCF utilised, and stan-
dardisation of the supernatant aspiration step, may be
required. Furthermore, a trend for decreased variability in
viable cell yield was also observed after the utilisation of
the non-centrifugation process step, which suggests that
the automated process step allowed for more consistent
viable hiPSC yields to be achieved.
Fig. 11 The mean viability of
pre-centrifugation, post-
centrifugation and non-
centrifugation hiPSC samples
over the pre-experimental (P34/
P22 ? 12) [replicates (n) = 4],
1st (P35/P22 ? 13) [replicates
(n) = 4], and 2nd (P36/
P22 ? 14) [replicates (n) = 6]
passages, and across four
batches. Standard deviations are
plotted as error bars. Asterisk
(*) denotes significance over
non-centrifugation hiPSCs
(p = 0.05). Number sign (#)
denotes significance over pre-
centrifugation hiPSCs in the 2nd
passage (p = 0.05)
Fig. 12 Average aggregate rate from pre-, post- and non-centrifuga-
tion hiPSC counts from all four batches over the pre-experimental
(P34/P22 ? 12) [replicates (n) = 4], 1st (P35/P22 ? 13) [replicates
(n) = 4], and 2nd (P36/P22 ? 14) [replicates (n) = 6] passages.
Standard deviations are plotted as error bars. Asterisk (*) denotes
significance of pre-experimental passage over 1st and 2nd passages
(p = 0.05). Number sign (#) denotes significance of pre-centrifuga-
tion hiPSCs over post-centrifugation hiPSCs (p = 0.05). Dagger
symbol () denotes significance of non-centrifugation hiPSCs over
post-centrifugation hiPSCs (p = 0.05)
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The greater aggregate rates observed in non-centrifu-
gation populations, and the decrease in aggregate rate
identified after the performance of the centrifugation pro-
cess step, indicate that the automated process step does not
allow for comparable aggregate dissipation to that of the
manual process step; and that the process of centrifugation
reduces the amount of cell aggregation. However, the
incorporated mixing steps performed after the non-cen-
trifugation cell count may partly mitigate this increased
aggregation. These findings suggest that the centrifugation
process step may be beneficial for the generation of a single
cell suspension, which is favourable for seeding the
VAX001024c07 hiPSC line and cell enumeration using the
Cedex automated cell counter.
The lower cell viabilities observed in non-centrifugation
populations may suggest that the automated process step
negatively impacted the viability of hiPSC populations,
which may be linked to the residual dissociation agent
carryover. However, the difference between the mean
viabilities for post-centrifugation and non-centrifugation
samples was B2.2 %, which is below the maximum intra-
sample variability in cell viability for the Cedex automated
cell counter (±3 %) [18], with the viability of non-cen-
trifugation populations remaining above 94 % throughout
the experiment. The increase in hiPSC viability observed
after the centrifugation process step may be associated with
the removal of debris and non-viable cells.
All hiPSC populations in this study demonstrated
B10 % SSEA-1 expression and C70 % TRA-1-81
expression, therefore, meeting the I-Stem criteria for
expression of these markers are required during manufac-
turing runs. However, only baseline and non-centrifugation
populations met the C70 % SSEA-3 expression criteria.
Furthermore, although the majority of hiPSCs in each
population co-expressed SSEA-3 and TRA-1-81, only non-
centrifugation hiPSC populations were shown to meet the
I-Stem criteria of C70 % co-expression of SSEA-3 and
TRA-1-81 pluripotency markers. Therefore, non-centrifu-
gation populations exhibited increased pluripotency marker
expression and decreased differentiation marker expression
compared to centrifugation hiPSCs, which may indicate
that the automated process step was favourable for the
maintenance of pluripotency in hiPSC cultures. Previous
studies have also identified a reduction in pluripotency
marker expression after centrifugation [3, 19].
This study also highlights the detrimental effect of the
cryopreservation and thawing processes upon hiPSC pop-
ulations, with these cells exhibiting larger cell diameters,
lower viable cell yields, greater population doubling times,
and greater aggregate rates in the first passage after
cryopreservation. It is, therefore, apparent that these cells
require one passage after cryopreservation to recover their
typical characteristics. However, the cryopreservation and
thawing processes did not impact hiPSC viability, which
may be due to the performance of daily medium exchanges
and the resultant removal of apoptotic cells.
Finally, this study demonstrates that an automated
hiPSC manufacturing process transfer between indepen-
dent laboratories can be successfully completed, allowing
for the generation of high hiPSC yields which predomi-
nantly co-express the SSEA-3 and TRA-1-81 pluripotency
markers. However, as a single hiPSC line was examined in
this study, further research is required to determine the way
in which other hiPSC lines derived from different donors
would respond to the utilisation of alternative process
steps. Furthermore, as three automated passages were
performed for each centrifugation and non-centrifugation
batch, the comparability between process steps over
extended culture cannot be determined from this study.
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Appendix
See Figs. 13 and 14.
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Fig. 13 a Top, b middle and c bottom. Baseline (a), centrifugation (b) and non-centrifugation (c) hiPSC isotype control multicolour flow
cytometry scatter plots
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